However, if a reporting company chooses not to file their BOI report ... if the company is obligated to comply with the CTA in its current form.

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program ...

After months of litigation—including a cameo before the Supreme Court—the last nationwide injunction of the Corporate Transparency Act (CTA) ...

ProQR may selectively form new partnerships, which could include multi-target ... clinical data readouts across multiple programs in 2025 and 2026, and the filing of a CTA application for our lead ...

In this episode of Tax Notes Talk, Melissa Wiley of Kostelanetz LLP provides an update on the Corporate Transparency Act’s legal status after Treasury announced it would not enforce penalties against ...

Meanwhile, there have been U.S. District Court cases that have held the CTA ... filing. Another situation where the BOI reporting requirement makes little sense is for folks who have received an ...

ProQR may selectively form new partnerships ... data readouts across multiple programs in 2025 and 2026, and the filing of a CTA application for our lead program, AX-0810, in Q2 2025, our Axiomer ...

Prime Medicine expects to file an investigational new drug (IND) and/or clinical trial application (CTA) in mid-2026 ... s most recent Annual Report on Form 10-K, as well as any subsequent ...

The expected filing of an IND and/or CTA in mid-2026 indicates a strategic ... in Prime Medicine’s most recent Annual Report on Form 10-K, as well as any subsequent filings with the Securities ...